Acute and Chronic Cardiovascular Manifestations of COVID-19: Role for Endotheliopathy
By: John P. Cooke, John H. Connor and Abhishek Jain
References
- Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol. 2020 Jul;20(7):389–391. doi: 10.1038/s41577-020-0343-0
- Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020 Sep 1;41(32):3038–3044. doi: 10.1093/eurheartj/ehaa623
- Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm Res. 2020 Dec;69(12):1181–1189. doi: 10.1007/s00011-020-01401-6
- Nagashima S, Mendes MC, Camargo Martins AP, et al. Endothelial Dysfunction and Thrombosis in Patients With COVID-19-Brief Report. Arterioscler Thromb Vasc Biol. 2020 Oct;40(10):2404–2407. doi: 10.1161/ATVBAHA.120.314860
- He L, Mäe MA, Muhl L, et al. Pericyte-specific vascular expression of SARS-CoV-2 receptor ACE2 – implications for microvascular inflammation and hypercoagulopathy in COVID-19. BioRxiv. 2020 May.2005.2011.088500. doi: 10.1101/2020.05.11.088500
- Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020 May 2;395(10234):1417–1418. doi: 10.1016/S0140-6736(20)30937-5
- McConnell MJ, Kawaguchi N, Kondo R, et al. Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. J Hepatol. 2021 Sep;75(3):647–658. doi: 10.1016/j.jhep.2021.04.050
- Kang S, Tanaka T, Inoue H, et al. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. Proc Natl Acad Sci U S A. 2020 Sep 8;117(36):22351–22356. doi: 10.1073/pnas.2010229117
- Li X, Sun X, Carmeliet P. Hallmarks of Endothelial Cell Metabolism in Health and Disease. Cell Metab. 2019 Sep 3;30(3):414–433. doi: 10.1016/j.cmet.2019.08.011
- Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J. 2013 Aug;34(31):2436–43. doi: 10.1093/eurheartj/eht149
- Vanhoutte PM, Shimokawa H, Feletou M, Tang EH. Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta Physiol (Oxf). 2017 Jan;219(1):22–96. doi: 10.1111/apha.12646
- Huang PL. eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab. 2009 Aug;20(6):295–302. doi: 10.1016/j.tem.2009.03.005
- Atochin DN, Huang PL. Role of endothelial nitric oxide in cerebrovascular regulation. Curr Pharm Biotechnol. 2011 Sep;12(9):1334–42. doi: 10.2174/138920111798280974
- Blum A, Giladi M, Weinberg M, et al. High anti-cytomegalovirus (CMV) IgG antibody titer is associated with coronary artery disease and may predict post-coronary balloon angioplasty restenosis. Am J Cardiol. 1998 Apr 1;81(7):866–8. doi: 10.1016/s0002-9149(98)00019-8
- Du Y, Zhang G, Liu Z. Human cytomegalovirus infection and coronary heart disease: a systematic review. Virol J. 2018 Feb 6;15(1):31. doi: 10.1186/s12985-018-0937-3
- Badawi
A, Di
Giuseppe
G,
Gupta
A,
Poirier
A,
Arora
P. Bayesian network
modelling study to identify factors influencing the risk of cardiovascular
disease in Canadian adults with hepatitis C virus infection.
BMJ Open. 2020
May
5;10(5):
e035867 . doi: 10.1136/bmjopen-2019-035867 - Hemmat N, Ebadi A, Badalzadeh R, Memar MY, Baghi HB. Viral infection and atherosclerosis. Eur J Clin Microbiol Infect Dis. 2018 Dec;37(12):2225–2233. doi: 10.1007/s10096-018-3370-z
- Gattone M, Iacoviello L, Colombo M, et al. Chlamydia pneumoniae and cytomegalovirus seropositivity, inflammatory markers, and the risk of myocardial infarction at a young age. Am Heart J. 2001 Oct;142(4):633–40. doi: 10.1067/mhj.2001.118118
- Nieto FJ, Adam E, Sorlie P, et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation. 1996 Sep 1;94(5):922–7. doi: 10.1161/01.cir.94.5.922
- Warren-Gash C, Hayward AC, Hemingway H, et al. Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study. J Infect Dis. 2012 Dec 1;206(11):1652–9. doi: 10.1093/infdis/jis597
- Peretz A, Azrad M, Blum A. Influenza virus and atherosclerosis. QJM. 2019 Oct 1;112(10):749–755. doi: 10.1093/qjmed/hcy305
- Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020 Jul 9;383(2):120–128. doi: 10.1056/NEJMoa2015432
- Lee J, Sayed N, Hunter A, et al. Activation of innate immunity is required for efficient nuclear reprogramming. Cell. 2012 Oct 26;151(3):547–58. doi: 10.1016/j.cell.2012.09.034
- Sayed N, Wong WT, Ospino F, et al. Transdifferentiation of human fibroblasts to endothelial cells: role of innate immunity. Circulation. 2015 Jan 20;131(3):300–9. doi: 10.1161/CIRCULATIONAHA.113.007394
- Meng S, Zhou G, Gu Q, Chanda PK, Ospino F, Cooke JP. Transdifferentiation Requires iNOS Activation: Role of RING1A S-Nitrosylation. Circ Res. 2016 Oct 14;119(9):e129–e138. doi: 10.1161/CIRCRESAHA.116.308263
- Lai L, Reineke E, Hamilton DJ, Cooke JP. Glycolytic Switch Is Required for Transdifferentiation to Endothelial Lineage. Circulation. 2019 Jan 2;139(1):119–133. doi: 10.1161/CIRCULATIONAHA.118.035741
- Dal-Pra
S,
Hodgkinson
CP,
Dzau
VJ. Induced
cardiomyocyte maturation: Cardiac transcription factors are necessary but
not sufficient. PLoS One. 2019
Oct
17;14(10):
e0223842 . doi: 10.1371/journal.pone.0223842 - Inciardi RM, Lupi L, Zaccone G, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Jul 1;5(7):819–824. doi: 10.1001/jamacardio.2020.1096
- Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Jul 1;5(7):811–818. doi: 10.1001/jamacardio.2020.1017
- Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Jul 1;5(7):802–810. doi: 10.1001/jamacardio.2020.0950
- Stephan BCM, Harrison SL, Keage HAD, Babateen A, Robinson L, Siervo M. Cardiovascular Disease, the Nitric Oxide Pathway and Risk of Cognitive Impairment and Dementia. Curr Cardiol Rep. 2017 Aug 11;19(9):87. doi: 10.1007/s11886-017-0898-y
- Stone J, Hangge P, Albadawi H, et al. Deep vein thrombosis: pathogenesis, diagnosis, and medical management. Cardiovasc Diagn Ther. 2017 Dec;7(Suppl 3):S276–S284. doi: 10.21037/cdt.2017.09.01
- National Center for Biotechnology
Information [Internet]. Bethesda,
MD: US National Library of Medicine;
c2021.
The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism ; 2008 [cited 2021 Oct 25]. Available from:https://www.ncbi.nlm.nih.gov/books/NBK44178/ - Ren B, Yan F, Deng Z, et al. Extremely High Incidence of Lower Extremity Deep Venous Thrombosis in 48 Patients With Severe COVID-19 in Wuhan. Circulation. 2020 Jul 14;142(2):181–183. doi: 10.1161/CIRCULATIONAHA.120.047407
- Wichmann D, Sperhake JP, Lütgehetmann M, et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med. 2020 Aug 18;173(4):268–277. doi: 10.7326/M20-2003
- Escher R, Breakey N, Lämmle B. Severe COVID-19 infection associated with endothelial activation. Thromb Res. 2020 Jun;190:62. doi: 10.1016/j.thromres.2020.04.014
- Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell. 2020 May 14;181(4):905–913.e7. doi: 10.1016/j.cell.2020.04.004
- Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol. 2020 Jul;20(7):389–391. doi: 10.1038/s41577-020-0343-0
- Mortus
JR,
Manek
SE,
Brubaker
LS, et al.
Thromboelastographic Results and Hypercoagulability Syndrome
in Patients With Coronavirus Disease 2019 Who Are Critically
Ill. JAMA Netw Open. 2020
Jun
1;3(6):
e2011192 . doi: 10.1001/jamanetworkopen.2020.11192 - Hanff TC, Mohareb AM, Giri J, Cohen JB, Chirinos JA. Thrombosis in COVID-19. Am J Hematol. 2020 Dec;95(12):1578–1589. doi: 10.1002/ajh.25982
- Lowe GDO. Virchow’s triad revisited: abnormal flow. Pathophysiol Haemost Thromb. 2003 Sep-2004 Dec;33(5–6):455–7. doi: 10.1159/000083845
- National Center for Biotechnology
Information [Internet]. Bethesda,
MD: US National Library of Medicine;
c2021. Rumbaut
RE,
Thiagarajan P.
Arterial, Venous, and Microvascular
Hemostasis/Thrombosis; 2008 [cited 2021 Oct 25]. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK53453/ - Rajeeva NK, Walther BK, Suresh R, Cooke JP, Jain A. Microengineered Human Vein-Chip Recreates Venous Valve Architecture and Its Contribution to Thrombosis. Small. 2020;16(49):2003401. doi: 10.1002/smll.202003401
- Pandian, NKR, Mannino RG, Lam WA, Jain A. Thrombosis-on-a-chip: Prospective impact of microphysiological models of vascular thrombosis. Curr Opin Biomed Eng. 2018 Mar;5:29–34. doi: 10.1016/j.cobme.2017.12.001
- Diaz JA, Obi AT, Myers DD, et al. Critical review of mouse models of venous thrombosis. Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):556–62. doi: 10.1161/ATVBAHA.111.244608
- Bazigou E, Makinen T. Flow control in our vessels: vascular valves make sure there is no way back. Cell Mol Life Sci. 2013 Mar;70(6):1055–66. doi: 10.1007/s00018-012-1110-6
- Diaz JA, Saha P, Cooley B, et al. Choosing a Mouse Model of Venous Thrombosis. Arterioscler Thromb Vasc Biol. 2019 Mar;39(3):311–318. doi: 10.1161/ATVBAHA.118.311818
- Ingber DE. Reverse Engineering Human Pathophysiology with Organs-on-Chips. Cell. 2016 Mar 10;164(6):1105–1109. doi: 10.1016/j.cell.2016.02.049
- Benam KH, Dauth S, Hassell B, et al. Engineered in vitro disease models. Annu Rev Pathol. 2015;10:195–262. doi: 10.1146/annurev-pathol-012414-040418
- Jain A, Graveline A, Waterhouse A, Vernet A, Flaumenhaft R, Ingber DE. A shear gradient-activated microfluidic device for automated monitoring of whole blood haemostasis and platelet function. Nat Commun. 2016 Jan 6;7:10176. doi: 10.1038/ncomms10176
- De Ceunynck K, Peters CG, Jain A, et al. PAR1 agonists stimulate APC-like endothelial cytoprotection and confer resistance to thromboinflammatory injury. Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):E982–E991. doi: 10.1073/pnas.1718600115
- Jain A, Barrile R, van der Meer AD, et al. Primary Human Lung Alveolus-on-a-chip Model of Intravascular Thrombosis for Assessment of Therapeutics. Clin Pharmacol Ther. 2018 Feb;103(2):332–340. doi: 10.1002/cpt.742
- Mathur T, Singh KA, Pandian NKR, et al. Organ-on-chips made of blood: endothelial progenitor cells from blood reconstitute vascular thromboinflammation in vessel-chips. Lab Chip. 2019 Jul 23;19(15):2500–2511. doi: 10.1039/c9lc00469f
- Luna DJ, Pandian NKR, Mathur T, et al. Tortuosity-powered microfluidic device for assessment of thrombosis and antithrombotic therapy in whole blood. Sci Rep 2020 Apr 1;10(1):5742. doi: 10.1038/s41598-020-62768-4
- Rubin R. As Their Numbers Grow, COVID-19 “Long Haulers” Stump Experts. JAMA. 2020 Oct 13;324(14):1381–1383. doi: 10.1001/jama.2020.17709
- Marshall M. The lasting misery of coronavirus long-haulers. Nature. 2020 Sep;585(7825):339–341. doi: 10.1038/d41586-020-02598-6
- WHO.int [Internet].
Geneva, Switzerland: World
Health Organization; c2021.
A clinical case definition of post COVID-19 condition by a Delphi consensus ; 2021 Oct 6 [cited 2021 Nov 10]. Available from:http://apps.who.int/iris/bitstream/handle/10665/345824/WHO-2019-nCoV-Post-COVID-19-condition-Clinical-case-definition-2021.1-eng.pdf . - Mehta JL, Bavineni M. Premature birth, infections, and atherosclerotic cardiovascular disease. Eur Heart J. 2019 Oct 14;40(39):3275. doi: 10.1093/eurheartj/ehz441
- Bavineni M, Wassenaar TM, Agnihotri K, Ussery DW, Lüscher TF, Mehta JL. Mechanisms linking preterm birth to onset of cardiovascular disease later in adulthood. Eur Heart J. 2019 Apr 7;40(14):1107–1112. doi: 10.1093/eurheartj/ehz025
- Miller JE, Hammond GC, Strunk T, et al. Association of gestational age and growth measures at birth with infection-related admissions to hospital throughout childhood: a population-based, data-linkage study from Western Australia. Lancet Infect Dis. 2016 Aug;16(8):952–61. doi: 10.1016/S1473-3099(16)00150-X
- Bekkering S, Miller JE, Burgner DP. Childhood infection may mediate the relationship between suboptimal intrauterine growth, preterm birth, and adult cardiovascular disease. Eur Heart J. 2019 Oct 14;40(39):3273–3274. doi: 10.1093/eurheartj/ehz438
- West HW, Juonala M, Gall SL, et al. Exposure to parental smoking in childhood is associated with increased risk of carotid atherosclerotic plaque in adulthood: the Cardiovascular Risk in Young Finns Study. Circulation. 2015 Apr 7;131(14):1239–46. doi: 10.1161/CIRCULATIONAHA.114.013485
DOI: https://doi.org/10.14797/mdcvj.1044 | Journal eISSN: 1947-6108
Language: English
Page range: 53 - 62
Submitted on: Sep 23, 2021
Accepted on: Oct 13, 2021
Published on: Dec 15, 2021
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2021 John P. Cooke, John H. Connor, Abhishek Jain, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.